All clinical isolates of group B Streptococcus (GBS; Streptococcus agalactiae) are considered uniformly susceptible to b-lactams, including penicillins. However, GBS with reduced penicillin susceptibility (PRGBS) were first identified by our group in Japan and have also been reported from North America. PRGBS are non-susceptible to penicillin because of acquisition of amino acid substitutions near the conserved active-site motifs in PBP2X. In particular, V405A and Q557E are considered the key amino acid substitutions responsible for penicillin non-susceptibility. We revealed that in addition to the substitutions in PBP2X, an amino acid substitution in PBP1A confers high-level cephalosporin resistance in GBS. As the number of publications on GBS with reduced b-lactam susceptibility (GBS-RBS), especially PRGBS, and concomitantly the need for a systematic classification of GBS-RBS is increasing, we propose here a classification of GBS-RBS based on the amino acid substitutions in their PBPs.
Introduction
Group B Streptococcus (GBS; Streptococcus agalactiae) is the major cause of neonatal sepsis and meningitis; it also causes invasive infections in the elderly and in people with underlying illness. 1 -3 At present, no approved vaccine to prevent GBS infections is available. Clinical isolates of GBS continue to be widely regarded as susceptible to b-lactams, with penicillin commonly being a first-line option for the treatment or prevention of GBS infections. However, we have identified GBS with reduced penicillin susceptibility (PRGBS) in Japan and these have also been reported from North America. 4 -16 PRGBS show non-susceptibility to penicillin due to the acquisition of amino acid substitutions near the active-site motifs in the transpeptidase domain of PBP2X. 4 -6 In particular, two amino acid substitutions in PBP2X, V405A and/or Q557E, are considered the key substitutions accounting for penicillin non-susceptibility. 4 Moreover, we have shown that in addition to substitutions in PBP2X, an amino acid substitution in PBP1A confers high-level resistance to cephalosporins in GBS. 13 Recently, penicillin-susceptible, but ceftibuten-resistant, GBS with amino acid substitutions in PBP2X were reported. 15 Because the number of publications on GBS with reduced b-lactam susceptibility (GBS-RBS) is increasing, a classification scheme for GBS-RBS, including PRGBS, based on the amino acid substitutions in their PBPs is very important to prevent future confusion in the nomenclature of GBS-RBS, including PRGBS.
Rationale for the classification of GBS-RBS
A substantial body of literature on b-lactam-non-susceptible clinical isolates of GBS is available. These publications are based solely on drug susceptibility tests and lack supportive molecular data on the mechanism of b-lactam non-susceptibility, e.g. sequence analysis data of the PBP genes. As phenotypic drug susceptibility tests are subjective and hence prone to potential measurement errors, we cannot rule out possible inaccuracies in the susceptibility data of b-lactam-non-susceptible clinical isolates described in these publications if PBP sequence data are not available. Moreover, as the reported penicillin MICs for PRGBS (0.25 -1 mg/L) 4 -6 are close to the 'susceptible' breakpoint (≤0.12 mg/L) as defined by the CLSI, international cooperation on antibiotic resistance research using a systematic approach is essential. Therefore, we propose a classification scheme for GBS-RBS clinical isolates, including PRGBS, for which the sequence data of the PBP genes are available.
Perspective on the classification of GBS-RBS
Our perspective on the classification of GBS-RBS based on amino acid substitutions in PBPs is outlined in Table 1 . First, we classified GBS-RBS into classes I -IV based on the distinct PBPs that harbour amino acid substitutions. Class I contains critical amino acid substitutions in PBP2X, but not in PBP1A, 1B, 2A or 2B. Although it is difficult to define a 'critical' amino acid substitution, we considered substitutions near the active-site motifs (within five amino acids) as 'critical' amino acid substitutions, except in PBP2X. Because amino acid substitutions in PBP2X are considered the first step of b-lactam non-susceptibility, we considered all substitutions in the transpeptidase domain of PBP2X as 'critical' amino acid substitutions. Class II contains critical amino acid substitutions in both PBP2X and PBP1A, but not in PBP1B, 2A or 2B. Class In addition, we divided each class into four subclasses, based on the key amino acid substitutions in PBP2X. Subclass 'a' of each class harbours the V405A substitution close to the 402 SSN 404 motif in PBP2X. Subclass 'b' contains the Q557E substitution close to the 552 KSG 554 motif. Subclass 'c' harbours both the V405A and Q557E substitutions. Subclass 'z' harbours neither V405A nor Q557E substitutions, but it harbours novel potentially critical amino acid substitutions in PBP2X. If other key amino acid substitutions in PBP2X are reported in the future or if the substitutions in PBP2X now classified under subclass 'z' are experimentally confirmed to be critical, novel subclasses can be added, e.g. subclass 'd', subclass 'e' etc.
Finally, we propose to add an asterisk to each class for which the amino acid substitutions in the PBPs have been proven critical by using molecular genetic techniques. For example, clinical isolate B1 belongs to IIb* because amino acid substitutions in PBP2X and PBP1A were shown to be critical by using allelic exchange experiments. 13 
Prospect of the classification of GBS-RBS
At present, the number of publications on the PBPs of GBS-RBS is increasing, owing to the ongoing emergence and discovery of novel b-lactam-non-susceptible clinical isolates. Concomitantly, the number of reported distinct amino acid substitution patterns in the PBPs will likely continue to increase. Therefore, we propose a classification scheme that is easily expandable with the increasing identifications of critical substitutions in PBPs.
For some b-lactam-non-susceptible clinical isolates, PBP gene sequence data are unfortunately missing. We recommend performing sequence analysis of the PBP genes for all b-lactam-nonsusceptible clinical isolates of GBS. Furthermore, when novel putative key amino acid substitutions in the PBPs are found, we recommend molecular genetic analyses including allelic exchange in order to reveal the importance of each amino acid substitution in the development of non-susceptibility to b-lactams.
We hope that this classification scheme for GBS-RBS will be adopted and expanded and that it will aid in predicting their b-lactam susceptibility profiles.
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